QIAGEN Reports Results for Third Quarter and First Nine Months of 2016
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
BofA/Merrill Lynch Upgrades Qiagen NV (QGEN) to Neutral
November 3, 2016 7:11 AM EDTBofA/Merrill Lynch upgraded Qiagen NV (NASDAQ: QGEN) from Underperform to Neutral.
For an analyst ratings summary and ratings history on Qiagen NV click here. For more ratings news on Qiagen NV click here.
Shares of Qiagen NV closed at $23.94 yesterday.
... MoreQiagen (QGEN) Tops Q3 EPS by 1c, Offers Outlook
November 2, 2016 4:05 PM EDTQiagen (NASDAQ: QGEN) reported Q3 EPS of $0.29, $0.01 better than the analyst estimate of $0.28. Revenue for the quarter came in at $338.7 million versus the consensus estimate of $336.04 million.
2016 outlook For the full-year 2016, QIAGEN continues to expect sales growth of about 6-7% CER, which is based on achieving the prior guidance (January 2016) for about 6% CER growth and the addition of about $10 million of first-time sales during the second half of the year from the Exiqon acquisition. About one percentage point of total CER growth is expected from the MO BIO acquisition (December 2015) and about five... More
